Roche's CellCept® (Mycophenolate Mofetil) Approved in China for Lupus Nephritis Treatment

Today (November 29), Roche’s oral medication CellCept® (generic name: mycophenolate mofetil) was officially launched in China for the indication of lupus nephritis. This indication was approved by the China National Medical Products Administration on October 30, making CellCept® the only mycophenolate mofetil currently approved in China for the treatment of lupus nephritis.

It is understood that "systemic lupus erythematosus" isAn autoimmune disease of unknown etiology,Named for its butterfly-shaped erythema, which resembles wolf bite marks.This “vicious wolf” not only disfigures appearance,, it can further invade vital organs,Causes various complications, including lupus nephritis.

Academician Liu Zhihong from the National Clinical Research Center for Kidney Diseases (Eastern Theater General Hospital) stated:Historically, the treatment regimen for lupus nephritis in China has primarily relied on combinations of non-selective immunosuppressants, specifically corticosteroids plus either cyclophosphamide or azathioprine, with a recommended duration of at least three years to prevent relapse. As a cytotoxic agent, cyclophosphamide carries significant toxic side effects; its long-term use can severely impair ovarian function and fertility in patients. Consequently, the exploration of appropriate therapeutic strategies aimed at enhancing efficacy while mitigating adverse effects has remained a focal point of both clinical practice and research in lupus nephritis.

Since its entry into the Chinese market in 1997, CellCept® has been successively approved for the prevention of organ rejection in patients receiving allogeneic kidney or liver transplantation. The current approval for the indication of lupus nephritis reflects the national drug regulatory authorities’ commitment to addressing clinical needs, based on real-world evidence and consistent recommendations from domestic and international guidelines and expert consensus.

Source: Roche Pharmaceuticals, with some content abridged